Literature DB >> 8478877

Interpretation and power of a pooled index.

C H Goldsmith1, H A Smythe, A Helewa.   

Abstract

OBJECTIVE: To describe, illustrate, provide statistical rationale and give clinical examples of the concept of a pooled index.
METHODS: No explicit design. Randomized control trials of patients diagnosed with rheumatoid arthritis from Rheumatic disease clinics, tertiary care hospitals and communities are used as examples to illustrate the pooled index technique. Interventions in rheumatic disease unit inpatient and outpatient care, occupational therapy and physiotherapy provided by Arthritis Society Therapists in the community were compared. Variables included active joint count, morning stiffness in min, mean of right and left grip strength in mm Hg, erythrocyte sedimentation rate in mm/h, a functional change score, and a pooled index.
RESULTS: The pooled index in each study detected a clinically important effect while individual measures were generally not able to declare the effect statistically significant.
CONCLUSIONS: The pooled index is a more powerful clinical outcome than any individual measure provided it is computed from at least 2 relevant clinical outcome measures that have low correlation with each other.

Entities:  

Mesh:

Year:  1993        PMID: 8478877

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  11 in total

Review 1.  Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa?

Authors:  T Pincus; T Sokka
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

Review 2.  [Measuring disease activity for rheumatoid arthritis].

Authors:  D Aletaha; T Stamm; J Smolen
Journal:  Z Rheumatol       Date:  2006-03       Impact factor: 1.372

3.  Adjuvant oestrogen therapy does not improve disease activity in postmenopausal patients with rheumatoid arthritis.

Authors:  H R van den Brink; A A van Everdingen; M J van Wijk; J W Jacobs; J W Bijlsma
Journal:  Ann Rheum Dis       Date:  1993-12       Impact factor: 19.103

4.  Perception of improvement in patients with rheumatoid arthritis varies with disease activity levels at baseline.

Authors:  D Aletaha; J Funovits; M M Ward; J S Smolen; T K Kvien
Journal:  Arthritis Rheum       Date:  2009-03-15

5.  Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?

Authors:  M J van der Veen; H J Dinant; C van Booma-Frankfort; G A van Albada-Kuipers; J W Bijlsma
Journal:  Ann Rheum Dis       Date:  1996-04       Impact factor: 19.103

6.  Treating rheumatoid arthritis to target: recommendations of an international task force.

Authors:  Josef S Smolen; Daniel Aletaha; Johannes W J Bijlsma; Ferdinand C Breedveld; Dimitrios Boumpas; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Maarten de Wit; Maxime Dougados; Paul Emery; Alan Gibofsky; Juan Jesus Gomez-Reino; Boulos Haraoui; Joachim Kalden; Edward C Keystone; Tore K Kvien; Iain McInnes; Emilio Martin-Mola; Carlomaurizio Montecucco; Monika Schoels; Désirée van der Heijde; Desirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-03-09       Impact factor: 19.103

7.  Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction.

Authors:  Josef S Smolen; José C Martinez Avila; Daniel Aletaha
Journal:  Ann Rheum Dis       Date:  2011-11-25       Impact factor: 19.103

8.  The many faces of psoriatic arthritis - a challenge to treatment to target?

Authors:  Daniel Aletaha
Journal:  Reumatologia       Date:  2016-03-23

9.  Responsiveness of a simple RAPID-3-like index compared to disease-specific BASDAI and ASDAS indices in patients with axial spondyloarthritis.

Authors:  Isabel Castrejón; Theodore Pincus; Daniel Wendling; Maxime Dougados
Journal:  RMD Open       Date:  2016-07-07

Review 10.  Do multiple outcome measures require p-value adjustment?

Authors:  Ronald J Feise
Journal:  BMC Med Res Methodol       Date:  2002-06-17       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.